Track topics on Twitter Track topics that are important to you
Celltrion is a biopharmaceutical manufacturing company dedicated to supplying the next generation of biopharmaceutical products to the global community. Our seasoned management team, favorable cost structure and strategic location in the rapidly growing Asian pharmaceutical markets make us an ideal choice for clients seeking world-class contract manufacturing services.
Celltrion's 23-acre manufacturing operation is located at the center of the high-technology park in Songdo New City, a new high-technology complex in the Incheon Metropolitan City , South Korea. The Celltrion facility is in close proximity to both the Incheon International Airport and downtown Seoul. Construction of Celltrion's 50,0000-liter capacity biopharmaceutical manufacturing facility, which is expected to be ready for commercial operation by early 2006, is being designed to comply with the cGMP (current Good Manufacturing Practices) Standards of the U.S. Food and Drug Administration and EMEA. The capacity can be quickly expanded to 150,000 liters based on client demand.
Phone: 82 32-850-5000
Fax: 82 32-850-5040
Celltrion won against Johnson & Johnson unit Janssen Biotech's patent-infringement lawsuit regarding Celltrion's biosimilar I -More-
The FDA issued two Complete Response Letters (CRLs) to South Korean manufacturer Celltrion. Teva Pharmaceutical Industries signed a deal in 2016 with Celltrion to commercialize the two biosimilars.
The FDA has rejected approval of Celltrion’s biologics license applications for Truxima, a proposed rituximab biosimilar, and Herzuma, a proposed trastuzumab biosimilar, issuing Complete Response Le...
INCHEON, South Korea–(BUSINESS WIRE)–Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed m...
The US FDA has issued complete response letters (CRL) for the Rituxan and Herceptin biosimilar candidates after Celltrionâs facility received a warning in Janaury.
INCHEON, South Korea–(BUSINESS WIRE)–Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P10 (rituximab),...
Celltrion has told shareholders its manufacturing site received a Form 483 from the US FDA.
It was no fluke when Celltrion Healthcare became the first drug developer to win approval for a biosimilar…
A new subcutaneous infliximab formulation is being developed by Celltrion, Inc. as an alternative to the intravenous regimen where subcutaneous infliximab injection typically takes less th...
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltr...
Based in Incheon, Republic of Korea, Celltrion, Inc. is a global biopharmaceutical leader with strong research and development capabilities in biosimilar monoclonal antibodies (mA...
Celltrion is a biopharmaceutical manufacturing company dedicated to supplying the next generation of biopharmaceutical products to the global community. Our seasoned management team, favorable cost ...
Satellite symposium 3a: Remsimaâ¢, the 1st biosimilar monoclonal antibody, Friday 20 February 07:15-08:15
We have published hundreds of Celltrion news stories on BioPortfolio along with dozens of Celltrion Clinical Trials and PubMed Articles about Celltrion for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celltrion Companies in our database. You can also find out about relevant Celltrion Drugs and Medications on this site too.
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...